Wu J, Xu S, Li Z, Cong B, Yang Z, Yang Z
Emerg Microbes Infect. 2025; 14(1):2467781.
PMID: 39945674
PMC: 11873982.
DOI: 10.1080/22221751.2025.2467781.
Litcher-Kelly L, Ozen A, Ollis S, Feldman H, Yaworsky A, Medrano P
Orphanet J Rare Dis. 2025; 20(1):68.
PMID: 39934837
PMC: 11817392.
DOI: 10.1186/s13023-024-03436-y.
Lin K, Mendell J, Davis J, Harnisch L
J Pharmacokinet Pharmacodyn. 2024; 51(6):905-917.
PMID: 39349796
PMC: 11579122.
DOI: 10.1007/s10928-024-09941-8.
Bildstein T, Charbit-Henrion F, Azabdaftari A, Cerf-Bensussan N, Uhlig H
Nat Rev Gastroenterol Hepatol. 2024; 21(10):687-709.
PMID: 39117867
DOI: 10.1038/s41575-024-00962-9.
Xue L, Li K, Jia Y, Yao D, Guo X, Zhang S
J Microbiol Biotechnol. 2024; 34(9):1789-1802.
PMID: 39113196
PMC: 11473614.
DOI: 10.4014/jmb.2405.05023.
Factors affecting decisions of an HMO Drug Exemptions Committee on individual patient requests for coverage of non-formulary drugs.
Topol Y, Weiss L, Lomnicky Y, Yifrach-Damari I, Markovits N, Loebstein R
Isr J Health Policy Res. 2024; 13(1):30.
PMID: 39004759
PMC: 11247773.
DOI: 10.1186/s13584-024-00617-9.
Double-Edged Sword: Exploring the Mitochondria-Complement Bidirectional Connection in Cellular Response and Disease.
Lin J, Hwang S, Luo H, Mohamud Y
Biology (Basel). 2024; 13(6).
PMID: 38927311
PMC: 11200454.
DOI: 10.3390/biology13060431.
Breaking Down Barriers: Epithelial Contributors to Monogenic IBD Pathogenesis.
Ouahed J, Griffith A, Collen L, Snapper S
Inflamm Bowel Dis. 2024; 30(7):1189-1206.
PMID: 38280053
PMC: 11519031.
DOI: 10.1093/ibd/izad319.
Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study.
Ozen A, Chongsrisawat V, Sefer A, Kolukisa B, Jalbert J, Meagher K
Lancet. 2024; 403(10427):645-656.
PMID: 38278170
PMC: 10979753.
DOI: 10.1016/S0140-6736(23)02358-9.
Pozelimab: First Approval.
Hoy S
Drugs. 2023; 83(16):1551-1557.
PMID: 37856038
DOI: 10.1007/s40265-023-01955-9.
Precision medicine in monogenic inflammatory bowel disease: proposed mIBD REPORT standards.
Uhlig H, Booth C, Cho J, Dubinsky M, Griffiths A, Grimbacher B
Nat Rev Gastroenterol Hepatol. 2023; 20(12):810-828.
PMID: 37789059
DOI: 10.1038/s41575-023-00838-4.
Special issue: the genetics of early onset inflammatory bowel disease (IBD) and diarrheal disorders.
Kurolap A, Feldman H
Hum Genet. 2023; 142(5):595-597.
PMID: 37106128
DOI: 10.1007/s00439-023-02566-w.
Beyond IBD: the genetics of other early-onset diarrhoeal disorders.
Stallard L, Siddiqui I, Muise A
Hum Genet. 2023; 142(5):655-667.
PMID: 36788146
PMC: 10182111.
DOI: 10.1007/s00439-023-02524-6.
CD55 Facilitates Immune Evasion by Borrelia crocidurae, an Agent of Relapsing Fever.
Arora G, Lynn G, Tang X, Rosen C, Hoornstra D, Sajid A
mBio. 2022; 13(5):e0116122.
PMID: 36036625
PMC: 9600505.
DOI: 10.1128/mbio.01161-22.
Management of Inborn Errors of Immunity in the Genomic Era.
Demir D, Asnaashari K, Rezaei N, Ozen A
Turk Arch Pediatr. 2022; 57(2):132-145.
PMID: 35383007
PMC: 9366268.
DOI: 10.5152/TurkArchPediatr.2022.22033.
CD55-deficiency in Jews of Bukharan descent is caused by the Cromer blood type Dr(a-) variant.
Kurolap A, Hagin D, Freund T, Fishman S, Henig N, Brazowski E
Hum Genet. 2022; 142(5):683-690.
PMID: 35314883
PMC: 8936040.
DOI: 10.1007/s00439-021-02428-3.
Congenital iRHOM2 deficiency causes ADAM17 dysfunction and environmentally directed immunodysregulatory disease.
Kubo S, Fritz J, Raquer-McKay H, Kataria R, Vujkovic-Cvijin I, Al-Shaibi A
Nat Immunol. 2021; 23(1):75-85.
PMID: 34937930
PMC: 11060421.
DOI: 10.1038/s41590-021-01093-y.
Tipping the balance: intricate roles of the complement system in disease and therapy.
Pouw R, Ricklin D
Semin Immunopathol. 2021; 43(6):757-771.
PMID: 34698894
PMC: 8547127.
DOI: 10.1007/s00281-021-00892-7.
Expanding Horizons in Complement Analysis and Quality Control.
Frazer-Abel A, Kirschfink M, Prohaszka Z
Front Immunol. 2021; 12:697313.
PMID: 34434189
PMC: 8381195.
DOI: 10.3389/fimmu.2021.697313.
Targeting the Complement Pathway in Malignant Glioma Microenvironments.
Zhu H, Yu X, Zhang S, Shu K
Front Cell Dev Biol. 2021; 9:657472.
PMID: 33869223
PMC: 8047198.
DOI: 10.3389/fcell.2021.657472.